Wilkes University NSG 552 - Psychopharmacology - Verified Revised Full Exam (2026-2027)
Wilkes University NSG 552
Psychopharmacology
Exams 1, 2, & 3 — Questions and Answers with
Explanations
Latest — Verified Revised Full Exam
A comprehensive, verified examination preparation resource aligned with Wilkes University NSG 552
graduate-level Psychopharmacology curriculum. This document contains exactly 300 multiple-choice questions
distributed across three progressive examinations and sixteen thematic sections, complete with high-confidence
answers and detailed psychopharmacology-specific rationales.
Examination Structure
Exam 1: Foundations of Psychopharmacology (Q1–Q100)
Sections 1–5: Neuroanatomy & Neurotransmission; Pharmacokinetics & Pharmacodynamics; Major
Neurotransmitter Systems; Antidepressants; Anxiolytics & Hypnotics.
Exam 2: Psychopharmacology Across Disorders (Q101–Q200)
Sections 6–11: Antipsychotics; Mood Stabilizers; ADHD Pharmacotherapy; Substance Use Disorder
Pharmacotherapy; Cognitive Enhancers; Special Populations & Pharmacogenomics.
Exam 3: Advanced Clinical Application and Practice (Q201–Q300)
Sections 12–16: Medication Selection & Initiation; Titration, Switching & Augmentation; Adverse Effects,
Monitoring & Management; Drug Interactions & Polypharmacy; Patient Education, Adherence & Ethical/Legal
Wilkes NSG 552 Psychopharmacology Exam | Page 1
,Wilkes University NSG 552 - Psychopharmacology - Verified Revised Full Exam (2026-2027)
Prescribing.
Cognitive Level Distribution: 25% Recall • 50% Application • 25% Analysis
Question Format: 75% Scenario-Based • 25% Direct Recall
Each question: Four options (A–D) with one verified correct answer and 3–5 sentence
psychopharmacology-specific rationale.
Wilkes NSG 552 Psychopharmacology Exam | Page 2
,Wilkes University NSG 552 - Psychopharmacology - Verified Revised Full Exam (2026-2027)
EXAM 1: Foundations of Psychopharmacology (Q1–Q100)
This examination covers foundational psychopharmacology concepts including neuroanatomy and
neurotransmission, pharmacokinetics and pharmacodynamics, the major neurotransmitter systems,
antidepressant pharmacology, and anxiolytic/hypnotic agents. Questions emphasize mechanism of action,
receptor pharmacology, drug interactions, and evidence-based selection of first-line agents for common
psychiatric conditions.
Section 1: Neuroanatomy, Neurotransmission, and Signal Transduction
(Neurons, Synapses, Receptors, & Second Messengers) — Q1–Q20
Q1: A PMHNP student is explaining the action potential to a colleague. Which statement
accurately describes the sequence of events during neuronal depolarization?
A. Voltage-gated potassium channels open first, followed by sodium channels, driving the membrane
potential toward -90 mV
B. Voltage-gated sodium channels open rapidly, allowing Na+ influx that drives the membrane
potential from -70 mV toward +30 mV [CORRECT]
C. Calcium channels open at the soma, triggering retrograde propagation toward dendrites
D. Chloride channels open first, hyperpolarizing the membrane to -90 mV before sodium influx begins
Correct Answer: B
Rationale: Action potential depolarization begins when voltage-gated sodium channels open in response to
threshold stimulation (-55 mV), allowing rapid Na+ influx that drives the membrane potential from resting -70
mV toward +30 mV. Potassium channels open later (delayed rectifier) to repolarize the membrane. Calcium
channels are primarily involved at synaptic terminals for vesicle release, not at the soma for initiating
depolarization. Chloride channel opening would hyperpolarize, not depolarize, the neuron. Verified against
Wilkes NSG 552 neurophysiology module and Stahl’s Essential Psychopharmacology.
Q2: A patient asks why their psychiatric medication takes weeks to work when
neurotransmitter levels change within hours. The PMHNP explains that receptor
downregulation and signal transduction cascade adaptations typically require how long to
manifest clinically?
A. 12-24 hours
B. 2-6 weeks [CORRECT]
C. 3-6 months
D. 12 months
Correct Answer: B
Rationale: Although synaptic neurotransmitter levels change within hours of starting an SSRI, clinical
antidepressant effects typically require 2-6 weeks because downstream signal transduction adaptations (cAMP,
CREBD, BDNF upregulation) and receptor downregulation take time. This delay explains the therapeutic lag.
The 12-24 hour window reflects pharmacokinetic changes only, not pharmacodynamic clinical response. The
3-6 month window describes maintenance phase stabilization rather than initial onset. Verified against Wilkes
Wilkes NSG 552 Psychopharmacology Exam | Page 3
, Wilkes University NSG 552 - Psychopharmacology - Verified Revised Full Exam (2026-2027)
NSG 552 pharmacodynamics module.
Q3: Which structure is the primary site of action for selective serotonin reuptake inhibitors
(SSRIs)?
A. Postsynaptic 5-HT2A receptors
B. Presynaptic serotonin transporter (SERT) [CORRECT]
C. Postsynaptic 5-HT1A receptors
D. Serotonin vesicular transporter (VMAT2)
Correct Answer: B
Rationale: SSRIs exert their primary mechanism by binding to and inhibiting the presynaptic serotonin
transporter (SERT), blocking reuptake of serotonin from the synaptic cleft. VMAT2 packages serotonin into
vesicles but is not the SSRI target (it is targeted by tetrabenazine). 5-HT1A and 5-HT2A are postsynaptic
receptors modulated indirectly by increased synaptic serotonin, not the direct SSRI binding site. Verified against
Wilkes NSG 552 neurotransmitter systems module.
Q4: A 28-year-old patient begins an SSRI. Within hours, synaptic serotonin increases, yet the
patient develops transient anxiety. This acute effect is primarily mediated by overstimulation
of which receptor?
A. 5-HT1A postsynaptic
B. 5-HT2A postsynaptic [CORRECT]
C. 5-HT3 postsynaptic
D. 5-HT1A somatodendritic autoreceptor
Correct Answer: B
Rationale: Acute SSRI-induced anxiety and jitteriness are mediated primarily by postsynaptic 5-HT2A receptor
overstimulation, as synaptic serotonin rises before somatodendritic 5-HT1A autoreceptors desensitize. The
5-HT1A somatodendritic autoreceptor initially inhibits neuronal firing (limiting serotonin release), but
desensitizes over 2 weeks. 5-HT3 stimulation causes nausea/GI upset, not primarily anxiety. Verified against
Wilkes NSG 552 serotonin receptor pharmacology content.
Q5: G-protein coupled receptors (GPCRs) utilize second messenger systems to amplify
signals. Which second messenger pathway is activated by D2 receptor stimulation?
A. Activation of adenylyl cyclase, increasing cAMP
B. Inhibition of adenylyl cyclase, decreasing cAMP [CORRECT]
C. Activation of phospholipase C, increasing IP3/DAG
D. Direct opening of sodium channels
Correct Answer: B
Rationale: D2 receptors are Gi-coupled, so stimulation inhibits adenylyl cyclase, decreasing intracellular cAMP
and reducing protein kinase A activity. This is the basis for dopaminergic regulation of motor and reward
circuits. D1 receptors (Gs-coupled) activate adenylyl cyclase. Phospholipase C/IP3/DAG is the Gq pathway
used by 5-HT2C, M1, and alpha-1 receptors. Direct ion channel opening characterizes ionotropic receptors (e.g.,
Wilkes NSG 552 Psychopharmacology Exam | Page 4
Wilkes University NSG 552
Psychopharmacology
Exams 1, 2, & 3 — Questions and Answers with
Explanations
Latest — Verified Revised Full Exam
A comprehensive, verified examination preparation resource aligned with Wilkes University NSG 552
graduate-level Psychopharmacology curriculum. This document contains exactly 300 multiple-choice questions
distributed across three progressive examinations and sixteen thematic sections, complete with high-confidence
answers and detailed psychopharmacology-specific rationales.
Examination Structure
Exam 1: Foundations of Psychopharmacology (Q1–Q100)
Sections 1–5: Neuroanatomy & Neurotransmission; Pharmacokinetics & Pharmacodynamics; Major
Neurotransmitter Systems; Antidepressants; Anxiolytics & Hypnotics.
Exam 2: Psychopharmacology Across Disorders (Q101–Q200)
Sections 6–11: Antipsychotics; Mood Stabilizers; ADHD Pharmacotherapy; Substance Use Disorder
Pharmacotherapy; Cognitive Enhancers; Special Populations & Pharmacogenomics.
Exam 3: Advanced Clinical Application and Practice (Q201–Q300)
Sections 12–16: Medication Selection & Initiation; Titration, Switching & Augmentation; Adverse Effects,
Monitoring & Management; Drug Interactions & Polypharmacy; Patient Education, Adherence & Ethical/Legal
Wilkes NSG 552 Psychopharmacology Exam | Page 1
,Wilkes University NSG 552 - Psychopharmacology - Verified Revised Full Exam (2026-2027)
Prescribing.
Cognitive Level Distribution: 25% Recall • 50% Application • 25% Analysis
Question Format: 75% Scenario-Based • 25% Direct Recall
Each question: Four options (A–D) with one verified correct answer and 3–5 sentence
psychopharmacology-specific rationale.
Wilkes NSG 552 Psychopharmacology Exam | Page 2
,Wilkes University NSG 552 - Psychopharmacology - Verified Revised Full Exam (2026-2027)
EXAM 1: Foundations of Psychopharmacology (Q1–Q100)
This examination covers foundational psychopharmacology concepts including neuroanatomy and
neurotransmission, pharmacokinetics and pharmacodynamics, the major neurotransmitter systems,
antidepressant pharmacology, and anxiolytic/hypnotic agents. Questions emphasize mechanism of action,
receptor pharmacology, drug interactions, and evidence-based selection of first-line agents for common
psychiatric conditions.
Section 1: Neuroanatomy, Neurotransmission, and Signal Transduction
(Neurons, Synapses, Receptors, & Second Messengers) — Q1–Q20
Q1: A PMHNP student is explaining the action potential to a colleague. Which statement
accurately describes the sequence of events during neuronal depolarization?
A. Voltage-gated potassium channels open first, followed by sodium channels, driving the membrane
potential toward -90 mV
B. Voltage-gated sodium channels open rapidly, allowing Na+ influx that drives the membrane
potential from -70 mV toward +30 mV [CORRECT]
C. Calcium channels open at the soma, triggering retrograde propagation toward dendrites
D. Chloride channels open first, hyperpolarizing the membrane to -90 mV before sodium influx begins
Correct Answer: B
Rationale: Action potential depolarization begins when voltage-gated sodium channels open in response to
threshold stimulation (-55 mV), allowing rapid Na+ influx that drives the membrane potential from resting -70
mV toward +30 mV. Potassium channels open later (delayed rectifier) to repolarize the membrane. Calcium
channels are primarily involved at synaptic terminals for vesicle release, not at the soma for initiating
depolarization. Chloride channel opening would hyperpolarize, not depolarize, the neuron. Verified against
Wilkes NSG 552 neurophysiology module and Stahl’s Essential Psychopharmacology.
Q2: A patient asks why their psychiatric medication takes weeks to work when
neurotransmitter levels change within hours. The PMHNP explains that receptor
downregulation and signal transduction cascade adaptations typically require how long to
manifest clinically?
A. 12-24 hours
B. 2-6 weeks [CORRECT]
C. 3-6 months
D. 12 months
Correct Answer: B
Rationale: Although synaptic neurotransmitter levels change within hours of starting an SSRI, clinical
antidepressant effects typically require 2-6 weeks because downstream signal transduction adaptations (cAMP,
CREBD, BDNF upregulation) and receptor downregulation take time. This delay explains the therapeutic lag.
The 12-24 hour window reflects pharmacokinetic changes only, not pharmacodynamic clinical response. The
3-6 month window describes maintenance phase stabilization rather than initial onset. Verified against Wilkes
Wilkes NSG 552 Psychopharmacology Exam | Page 3
, Wilkes University NSG 552 - Psychopharmacology - Verified Revised Full Exam (2026-2027)
NSG 552 pharmacodynamics module.
Q3: Which structure is the primary site of action for selective serotonin reuptake inhibitors
(SSRIs)?
A. Postsynaptic 5-HT2A receptors
B. Presynaptic serotonin transporter (SERT) [CORRECT]
C. Postsynaptic 5-HT1A receptors
D. Serotonin vesicular transporter (VMAT2)
Correct Answer: B
Rationale: SSRIs exert their primary mechanism by binding to and inhibiting the presynaptic serotonin
transporter (SERT), blocking reuptake of serotonin from the synaptic cleft. VMAT2 packages serotonin into
vesicles but is not the SSRI target (it is targeted by tetrabenazine). 5-HT1A and 5-HT2A are postsynaptic
receptors modulated indirectly by increased synaptic serotonin, not the direct SSRI binding site. Verified against
Wilkes NSG 552 neurotransmitter systems module.
Q4: A 28-year-old patient begins an SSRI. Within hours, synaptic serotonin increases, yet the
patient develops transient anxiety. This acute effect is primarily mediated by overstimulation
of which receptor?
A. 5-HT1A postsynaptic
B. 5-HT2A postsynaptic [CORRECT]
C. 5-HT3 postsynaptic
D. 5-HT1A somatodendritic autoreceptor
Correct Answer: B
Rationale: Acute SSRI-induced anxiety and jitteriness are mediated primarily by postsynaptic 5-HT2A receptor
overstimulation, as synaptic serotonin rises before somatodendritic 5-HT1A autoreceptors desensitize. The
5-HT1A somatodendritic autoreceptor initially inhibits neuronal firing (limiting serotonin release), but
desensitizes over 2 weeks. 5-HT3 stimulation causes nausea/GI upset, not primarily anxiety. Verified against
Wilkes NSG 552 serotonin receptor pharmacology content.
Q5: G-protein coupled receptors (GPCRs) utilize second messenger systems to amplify
signals. Which second messenger pathway is activated by D2 receptor stimulation?
A. Activation of adenylyl cyclase, increasing cAMP
B. Inhibition of adenylyl cyclase, decreasing cAMP [CORRECT]
C. Activation of phospholipase C, increasing IP3/DAG
D. Direct opening of sodium channels
Correct Answer: B
Rationale: D2 receptors are Gi-coupled, so stimulation inhibits adenylyl cyclase, decreasing intracellular cAMP
and reducing protein kinase A activity. This is the basis for dopaminergic regulation of motor and reward
circuits. D1 receptors (Gs-coupled) activate adenylyl cyclase. Phospholipase C/IP3/DAG is the Gq pathway
used by 5-HT2C, M1, and alpha-1 receptors. Direct ion channel opening characterizes ionotropic receptors (e.g.,
Wilkes NSG 552 Psychopharmacology Exam | Page 4
